S. A. Ibragimova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
S. A. Ibragimova has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Aishat A. Udagova
Endocrinology Research Centre
2 shared publications - Ramazan Maksudovich Gabibullaev
Endocrinology Research Centre
2 shared publications - A. A. Belousova
Pirogov Russian National Research Medical University
1 shared publication - A. A. Pak
Russian University of Medicine
1 shared publication - Albert R. Powers
Department of Psychiatry, Yale University, New Haven, USA
1 shared publication - B. M. Babatova
Pirogov Russian National Research Medical University (Pirogov University)
1 shared publication
Latest Publications
- Open Access
Persisting perceptual abnormalities in psychedelic users are associated with conditioned hallucinations and impaired sensory processing
Serotonergic psychedelics (SP) are increasingly used in clinical research and naturalistic settings, but their psychotic-like side effects, including persisting perceptual abnormalities (PPAs), are poorly understood. Psychosis-associated hallucinations are associated with susceptibility to conditioned hallucinations and computationally-estimated overweighting of perceptual expectations, or priors. However, SPs are widely argued to reduce prior weighting. We surveyed 186 naturalistic SP users on prior SP use, SP-associated PPA history, and current PPAs. Participants completed the visual conditioned hallucinations (VCH) task, in which conditioning induces perception of absent stimuli. Behavioral data were used to fit parameters of a computational model to estimate latent states driving percepts and responses. Past and current PPAs were associated with younger age at first use and higher SP doses, lower visual thresholds, higher VCH rate and confidence, and reduced sensory discrimination. Among model parameters, however, only reduced decision precision tracked both measures and mediated the dose-PPA relationship; relative prior weighting rose equivocally, as expected when priors and sensory evidence gain precision together. SP-related PPAs may therefore arise from a noisy visual system biased toward detection, in which priors act as templates that convert sensory noise into expected percepts. These findings may point to a tractable model for how psychotic-like perception emerges.
Open AccessPersisting perceptual abnormalities in psychedelic users are associated with conditioned hallucinations and impaired sensory processing
Serotonergic psychedelics (SP) are increasingly used in clinical research and naturalistic settings, but their psychotic-like side effects, including persisting perceptual abnormalities (PPAs), are poorly understood. Psychosis-associated hallucinations are associated with susceptibility to conditioned hallucinations and computationally-estimated overweighting of perceptual expectations, or priors. However, SPs are widely argued to reduce prior weighting. We surveyed 186 naturalistic SP users on prior SP use, SP-associated PPA history, and current PPAs. Participants completed the visual conditioned hallucinations (VCH) task, in which conditioning induces perception of absent stimuli. Behavioral data were used to fit parameters of a computational model to estimate latent states driving percepts and responses. Past and current PPAs were associated with younger age at first use and higher SP doses, lower visual thresholds, higher VCH rate and confidence, and reduced sensory discrimination. Among model parameters, however, only reduced decision precision tracked both measures and mediated the dose-PPA relationship; relative prior weighting rose equivocally, as expected when priors and sensory evidence gain precision together. SP-related PPAs may therefore arise from a noisy visual system biased toward detection, in which priors act as templates that convert sensory noise into expected percepts. These findings may point to a tractable model for how psychotic-like perception emerges.
- Open Access
- 15 July 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (2) , 233-240
Diagnostic challenges of primary aldosteronism in a patient with chronic kidney disease and resistant arterial hypertension: a case report
Primary aldosteronism is a common cause of secondary arterial hypertension; however, its recognition may be substantially complicated by concomitant chronic kidney disease. Altered regulation of the renin-angiotensin- aldosterone system (RAAS), the effects of antihypertensive therapy, and the absence of typical laboratory features may create an atypical diagnostic profile and delay diagnosis. This article presents a clinical case of primary aldosteronism in a young patient with chronic kidney disease and resistant arterial hypertension, characterized by the absence of hypokalemia and by non-suppressed renin at the initial evaluation. After confirmatory testing and withdrawal of therapy affecting the RAAS, adrenalectomy was performed, and morphological and immunohistochemical examination confirmed an aldosterone-producing adenoma. This case illustrates the limitations of standard screening criteria and highlights the need for comprehensive interpretation of clinical, laboratory, and morphological findings when primary aldosteronism is suspected in patients with chronic kidney disease.
- 15 July 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (2) , 233-240
Open AccessDiagnostic challenges of primary aldosteronism in a patient with chronic kidney disease and resistant arterial hypertension: a case report
Primary aldosteronism is a common cause of secondary arterial hypertension; however, its recognition may be substantially complicated by concomitant chronic kidney disease. Altered regulation of the renin-angiotensin- aldosterone system (RAAS), the effects of antihypertensive therapy, and the absence of typical laboratory features may create an atypical diagnostic profile and delay diagnosis. This article presents a clinical case of primary aldosteronism in a young patient with chronic kidney disease and resistant arterial hypertension, characterized by the absence of hypokalemia and by non-suppressed renin at the initial evaluation. After confirmatory testing and withdrawal of therapy affecting the RAAS, adrenalectomy was performed, and morphological and immunohistochemical examination confirmed an aldosterone-producing adenoma. This case illustrates the limitations of standard screening criteria and highlights the need for comprehensive interpretation of clinical, laboratory, and morphological findings when primary aldosteronism is suspected in patients with chronic kidney disease.
- 16 June 2026
- Published by Endocrinology Research Centre in Clinical and experimental thyroidology
- Vol. 21 (3) , 23-31
Molecular Epigenetic Modulation of Immune Tolerance in Graves' Disease: The Role of Short-Chain Fatty Acids in the Regulation of TRAb Synthesis
Graves’ disease is a systemic autoimmune process characterized by persistent breakdown of immune tolerance and continued presence of thyrotropin receptor autoantibodies (TRAb), even after radical thyroidectomy. This review examines the role of the “gut–thyroid axis” as a key regulator of systemic immune homeostasis. Particular attention is paid to short-chain fatty acids (SCFAs) — microbial metabolites that act as potent epigenetic modulators. The mechanisms of histone deacetylase (HDAC) inhibition by butyrate and propionate are described in detail, which promote stabilization of Foxp3 gene expression in regulatory T cells and suppression of B-lymphocyte differentiation factors (AID, Blimp-1). The interplay between intestinal dysbiosis, increased barrier permeability, and uncontrolled autoantibody production is analyzed. In conclusion, prospective targeted therapeutic strategies are discussed, fecal microbiota transplantation (FMT), and the use selective HDAC inhibitors aimed at restoring immune control in refractory forms of the disease.
- 16 June 2026
- Published by Endocrinology Research Centre in Clinical and experimental thyroidology
- Vol. 21 (3) , 23-31
Molecular Epigenetic Modulation of Immune Tolerance in Graves' Disease: The Role of Short-Chain Fatty Acids in the Regulation of TRAb Synthesis
Graves’ disease is a systemic autoimmune process characterized by persistent breakdown of immune tolerance and continued presence of thyrotropin receptor autoantibodies (TRAb), even after radical thyroidectomy. This review examines the role of the “gut–thyroid axis” as a key regulator of systemic immune homeostasis. Particular attention is paid to short-chain fatty acids (SCFAs) — microbial metabolites that act as potent epigenetic modulators. The mechanisms of histone deacetylase (HDAC) inhibition by butyrate and propionate are described in detail, which promote stabilization of Foxp3 gene expression in regulatory T cells and suppression of B-lymphocyte differentiation factors (AID, Blimp-1). The interplay between intestinal dysbiosis, increased barrier permeability, and uncontrolled autoantibody production is analyzed. In conclusion, prospective targeted therapeutic strategies are discussed, fecal microbiota transplantation (FMT), and the use selective HDAC inhibitors aimed at restoring immune control in refractory forms of the disease.